Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Eisai Looks To MGI Pharma Acquisition For Growth

This article was originally published in PharmAsia News

Executive Summary

Japan's Eisai is looking to expanded sales of MGI Pharma in its home country of the United States for the acquiring company's own improvement. MGI's CEO Lonnie Moulder expects Eisai's acquisition to be symbiotic, with Eisai's sales staff combining with MGI's to put 900 representatives on the ground in the United States. Eisai looks to the MGI tie to counteract a reduction it faces in its own drug pipeline as patents on key products expire. Other Japanese drug makers have chosen to merge with each other. (Click here for more - a subscription may be required

You may also be interested in...



Eisai To File Dacogen sNDA for Out-Patient MDS, Despite Less Than Stellar Survival Data

TOKYO - As part of its strategy to reinforce its oncology and innovative pharmaceutical products, Eisai July 1 said its ongoing clinical trial comparing Dacogen with best supportive care in elderly patients with myelodysplastic syndromes, a bone marrow disease, had registered results that would enable the company to submit for applying the treatment on an out-patient basis, instead of in-hospital treatment

Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

FDA’s Final MOU On Interstate Compounding Now Awaits Signatures From States

US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.

UsernamePublicRestriction

Register

ID1132375

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel